Santhera Pharmaceuticals Holding AG
SANN
Rang in aandelen
#16590
Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company,... Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and sells medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the Europe, North America, and Asia. The company’s lead pipeline candidate includes Vamorolone, which is developed for the treatments of Duchenne muscular dystrophy. Its clinical stage pipeline also comprises Lonodelestat for the treatment of cystic fibrosis and other neutrophilic pulmonary diseases. Santhera Pharmaceuticals Holding AG was founded in 2004 and is based in Pratteln, Switzerland.
Aandeelprijs
$17.23
Marktkapitalisatie
$263.68M
Verandering (1 dag)
-4.18%
Verandering (1 jaar)
38.54%
Land
CH
Handel Santhera Pharmaceuticals Holding AG (SANN)
Categorie
Healthcare
Koersgeschiedenis voor Santhera Pharmaceuticals Holding AG (SANN)
Hoogste slotkoers: $18.92 op 2026-10-01
Laagste slotkoers: $44.13 op 2014-03-01
Laagste slotkoers: $44.13 op 2014-03-01
Koersgeschiedenis van Santhera Pharmaceuticals Holding AG van 2014 tot 2026
Jaarlijkse koersprestatie
| Jaar | Prestaties |
|---|---|
| 2026 (TTM) | 22.24% |
| 2025 | 42.98% |
| 2024 | -6.16% |
| 2023 | 41.12% |
| 2022 | -43.82% |
| 2021 | -53.14% |
| 2020 | -74.39% |
| 2019 | -17.31% |
| 2018 | -49.89% |
| 2017 | -38.99% |
| 2016 | -48.52% |
| 2015 | -16.32% |
| 2014 | 0.00% |
Aandelenkoers van vergelijkbare bedrijven of concurrenten
| Bedrijf | Aandelenkoers | Verandering 1jr% | Land |
|---|---|---|---|
| $536.13 | 25.72% |
US
|
|
| $200.12 | 645.31% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $291.76 | 2.51% |
BE
|
|
| $880.01 | 8.09% |
NL
|
